Mon Oct 14 11:23:08 UTC 2024: ## ADHD in Adults: New Data Highlights Treatment Gaps and Telehealth Use
**Washington, D.C. (October 10, 2024)** – A recent study by the Centers for Disease Control and Prevention (CDC) has shed light on the prevalence and treatment of attention-deficit/hyperactivity disorder (ADHD) in U.S. adults. The study, published in the Morbidity and Mortality Weekly Report (MMWR), reveals that an estimated 15.5 million adults in the U.S. have a current ADHD diagnosis, with nearly half receiving their diagnosis in adulthood.
The research, based on data collected in October-November 2023, found that approximately one third of adults with ADHD were not receiving any treatment, highlighting a significant gap in care. The study also uncovered concerns about medication availability, with 71.5% of adults who take stimulant medications for ADHD reporting difficulty filling their prescriptions due to shortages.
The report emphasizes the growing role of telehealth in ADHD care. Almost half of adults with ADHD reported ever using telehealth services for their condition, demonstrating a potential solution for improving access to diagnosis and treatment.
“This report provides crucial information on the scale of ADHD as a public health issue in adults,” said Dr. Brooke S. Staley, lead author of the study. “It highlights the need for increased awareness, improved access to diagnosis and treatment, and the potential benefits of telehealth in addressing ADHD care.”
The study’s findings have significant implications for policymakers, healthcare professionals, and individuals with ADHD. The CDC recommends using the data to:
* Develop and evaluate policies related to ADHD clinical care for adults.
* Address access to prescription stimulant medications.
* Ensure the appropriate implementation of telehealth services for ADHD care.
The CDC emphasizes the importance of ensuring an adequate supply of stimulant medications and addressing the risks associated with medication shortages. Additionally, the agency recommends the development of comprehensive clinical guidelines for ADHD in adults, to improve standards of care and health outcomes for this population.
The report underscores the need for continued research and advocacy to address the challenges of ADHD diagnosis, treatment, and medication access for adults. The CDC remains committed to supporting efforts to improve the lives of individuals with ADHD and ensure they receive the care they need.
First Piper 